Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma

Transfus Clin Biol. 2022 Feb;29(1):101-102. doi: 10.1016/j.tracli.2021.07.006. Epub 2021 Jul 29.

Authors

Massimo Franchini¹, Fausto Baldanti², Elena Percivalle², Alessandro Ferrari², Pietro Biasi³, Giancarlo Maria Liumbruno³, Claudia Glingani³

Affiliations

¹ Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, Italy. Electronic address: massimo.franchini@asst-mantova.it.
² Molecular Virology Unit, Microbiology and Virology Department, IRCCS Policlinico San Matteo, Pavia, Italy.
³ Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, Italy.

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Neutralizing*
Antibodies, Viral
COVID-19 Serotherapy
COVID-19* / therapy
Humans
Immunization, Passive
SARS-CoV-2
Technology

Substances

Antibodies, Neutralizing
Antibodies, Viral